Tokyo, Japan

Chisato Nakama

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 9(Granted Patents)


Location History:

  • Ibaraki, JP (2011)
  • Tokyo, JP (2013)

Company Filing History:


Years Active: 2011-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Chisato Nakama: Innovator in Diabetes Treatment

Introduction

Chisato Nakama is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating diabetes and related conditions. With a total of 2 patents, her work is recognized for its potential impact on healthcare.

Latest Patents

Nakama's latest patents include innovative compounds that serve as GPR120 agonists. The first patent describes a phenyl-isoxazol-3-ol derivative, which is useful for the treatment of diabetes mellitus or hyperlipidemia. This compound is represented by a specific formula that includes various substituents, enhancing its therapeutic potential. The second patent focuses on aryloxy-substituted benzimidazole derivatives, which act as glucokinase activators. These compounds are designed to provide treatments for diabetes and its complications, such as retinopathy and nephropathy.

Career Highlights

Chisato Nakama is currently employed at MSD K.K., where she continues to advance her research in pharmaceutical innovations. Her work is characterized by a commitment to developing effective treatments that address critical health issues.

Collaborations

Nakama collaborates with esteemed colleagues, including Noriaki Hashimoto and Yasuhiro Sasaki. These partnerships enhance her research efforts and contribute to the development of groundbreaking therapies.

Conclusion

Chisato Nakama's contributions to diabetes treatment through her innovative patents highlight her role as a leading inventor in the pharmaceutical industry. Her work not only showcases her expertise but also promises to improve the lives of many individuals affected by diabetes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…